Another result from this study showed that treatment with isoflavones (ERβ agonists) inhibited finasteride-induced EGFR nuclear translocation during prostatic hyperplasia (BPH) treatment (28). The gene discussed is EGFR; the disease is benign prostatic hyperplasia.